Cadila Healthcare Limited

Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial

Older News

AHMEDABAD, India, June 21, 2010 - Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy